Stop the virus from entering clinical trials with domestic anti-AIDS drugs before the invasion

According to the Shanghai branch of the Chinese Academy of Sciences, China has independent intellectual property rights of the new anti-AIDS candidate "Nifiviro" has been approved by the State FoodDrug administrationSupervision Administration into clinical trials" Nifivero "effectively blocks HIV before the invasion, and its anti-infection effect is comparable to that of similar international candidate drugs, which were developed by two Shanghai scientists."It is reported that the current clinical use of anti-AIDS drugs, generally act after the virus invades human cells, so that AIDS patients in the late stage to reduce the occurrence of death and complications, prolong their survival timeHowever, these drugs have obvious toxic side effects, and because the effect of use alone is not obvious, need to be used in combination with other anti-AIDS drugs, expensiveAt present, scientists in various countries began to target anti-AIDS drug research, to a chemo-factor receptor called CCR v, one of the researchers at The Institute of Organic Chemistry of theChinese Academy of Sciences, said,CCR V is widely present in the normal human immune cell membrane,and is also a key "medium" to help HIV invade cellsAfter more than a hundred screening, they foundthat a compound can effectively block theof the 'vector' functioning, to inhibit the virus from entering the cell body Ma said , "Nifivero" the greatest significance is to move the line of defense from after the INVASION of HIV, forward to the invasion before the invasion As for when the new drug will go on the market, Ma said, in general, clinical trials of new drugs need at least three years, when AIDS patients can use "nifiverovo", but also depends on the results of clinical trials As for the price, he said, "Nifivero" is a state-owned brand, after the market should be cheaper than similar international drugs (
reprinted from "China News Network")